Tüdőrák: vizsgálatok itt: Kína
1144 trials · From ClinicalTrials.gov, checked 2026. november 16.. Ask the study team whether a trial fits you.
- No phaseTaking peopleClinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)
- Where
- Beijing, Changsha, Fuzhou, Guangdong, Guangzhou, Hangzhou, Hebei, Hefei, Hubei, Jiangsu, Jiangxi, Jinan, Jinzhou, Nanchang, Nanning, Shandong, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Taiyuan, Xiamen, Zhejiang, Zhengzhou
- Életkor
- 18 év and over
- People
- 150
- Run by
- Daiichi Sankyo
See details and how to joinNCT06809764 - 2. fázisNot yet taking people in KínaA Multicenter Exploratory Clinical Study of Iruplaltinib Combined With Pemetrexed as Neoadjuvant Therapy for Resectable ALK-Positive Non-Squamous Non-Small Cell Lung Cancer
- Where
- Fuzhou, Longyan, Quanzhou, Xiamen, Zhangzhou
- Életkor
- 18 év to 75 év
- People
- 30
- Run by
- First Affiliated Hospital of Fujian Medical University
See details and how to joinNCT07771764 - 2. fázisTaking peopleAssessment of Adebelizumab Combined With Chemotherapy in Concurrent Radiotherapy Versus Sequential Radiotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 60
- Run by
- Peking University Cancer Hospital & Institute
See details and how to joinNCT06768307 - 1. fázisTaking peopleA Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
- Where
- Beijing, Changsha, Guangzhou, Jinan, Jining, Shanghai, Shenyang, Shijiazhuang
- Életkor
- 18 év and over
- People
- 738 worldwide
- Run by
- NextCure, Inc.
See details and how to joinNCT06792552 - No phaseTaking peopleAcupoint Application for Chemotherapy-Induced Nausea and Vomiting in Lung Cancer
- Where
- Chongqing
- Életkor
- 18 év to 75 év
- People
- 60
- Run by
- Xiu Huang
See details and how to joinNCT07768124 - 3. fázisTaking peopleTo Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy
- Where
- Suzhou
- Életkor
- 18 év to 75 év
- People
- 318
- Run by
- Allist Pharmaceuticals, Inc.
See details and how to joinNCT04853342 - 1/2. fázisTaking peopleA Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1
- Where
- Beijing, Changchun, Changsha, Chongqing, Hangzhou, Harbin, Hohhot, Hubei, Nanning, Shenyang, Shenzhen, Shijiazhuang, Xiamen, Xi’an, Zhengzhou
- Életkor
- 18 év and over
- People
- 104
- Run by
- Allist Pharmaceuticals, Inc.
See details and how to joinNCT05276726 - 1/2. fázisTaking peoplePhase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
- Where
- Beijing, Changsha, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Hohhot, Jinan, Linyi, Shanghai, Shenyang, Shenzhen, Wuhan, Xiamen, Zhengzhou
- Életkor
- 18 év and over
- People
- 240
- Run by
- Allist Pharmaceuticals, Inc.
See details and how to joinNCT05288205 - 3. fázisTaking peopleJAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation
- Where
- Beijing, Cangzhou, Changsha, Chengdu, Fuzhou, Guangzhou, Haerbin, Hangzhou, Hefei, Jilin City, Jinan, Linyi, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Taiyuan, Taizhou, Tianjin, Wuhan, Wuxi, Xi’an, Zhengzhou
- Életkor
- 18 év and over
- People
- 392
- Run by
- Allist Pharmaceuticals, Inc.
See details and how to joinNCT06416410 - 1. fázisTaking peopleA Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AST2303 Tablets (ABK3376 Tablets) in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 120
- Run by
- Allist Pharmaceuticals, Inc.
See details and how to joinNCT06955988 - 3. fázisTaking peopleFirmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation
- Where
- Beijing, Shandong
- Életkor
- 18 év and over
- People
- 300
- Run by
- Allist Pharmaceuticals, Inc.
See details and how to joinNCT06956001 - 3. fázisTaking peopleA Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases
- Where
- Guangdong
- Életkor
- 18 év and over
- People
- 380
- Run by
- Allist Pharmaceuticals, Inc.
See details and how to joinNCT06970639 - 3. fázisTaking peopleEffect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer
- Where
- Changsha
- Életkor
- 18 év to 75 év
- People
- 186
- Run by
- Hunan Province Tumor Hospital
See details and how to joinNCT07251582 - No phaseTaking peopleReal-World Outcomes of Resected EGFR-Mutated NSCLC Patients Treated With Adjuvant EGFR-TKI in China
- Where
- Beijing, Chengdu, Fuzhou, Guangzhou, Nanchang, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xi'an, Xuzhou, Zhengzhou
- Életkor
- 18 év and over
- People
- 2000
- Run by
- AstraZeneca
See details and how to joinNCT07593248 - No phaseTaking peoplePhase II Trial of Consolidative Thoracic Radiotherapy for ES-SCLC After Standard Care of Chemo-immunotherapy
- Where
- Shanghai
- Életkor
- 18 év to 80 év
- People
- 104
- Run by
- Ruijin Hospital
See details and how to joinNCT05552846 - 2. fázisTaking peopleSKB264 in Combination With SKB118 for Non-Small Cell Lung Cancer
- Where
- Jilin City, Shanghai
- Életkor
- 18 év to 75 év
- People
- 206
- Run by
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
See details and how to joinNCT07697586 - 2. fázisTaking peopleNK Cells Plus ICI for SCLC Maintenance
- Where
- Tianjin
- Életkor
- 18 év and over
- People
- 42
- Run by
- Tianjin First Central Hospital
See details and how to joinNCT07759856 - No phaseTaking peopleAcupressure for Cough in Lung Cancer Survivors
- Where
- Shenzhen
- Életkor
- 18 év and over
- People
- 80 worldwide
- Run by
- The University of Hong Kong
See details and how to joinNCT07315672 - 1/2. fázisTaking peopleAMT-116 in Combination With AK112 in Patients With Lung Cancer
- Where
- Guangzhou, Hangzhou
- Életkor
- 18 év to 75 év
- People
- 118
- Run by
- Multitude Therapeutics Inc.
See details and how to joinNCT07590531 - 3. fázisTaking peopleA Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D Mutation
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 300
- Run by
- Genfleet Therapeutics (Shanghai) Inc.
See details and how to joinNCT07668752 - 4. fázisTaking peopleOral Paclitaxel Solution With Immunotherapy and Concurrent SBRT as Neoadjuvant Treatment for Older Adults With NSCLC
- Where
- Guangzhou, Hangzhou, Lishui, Shanghai, Suqian
- Életkor
- 70 év and over
- People
- 78
- Run by
- Shanghai Pulmonary Hospital, Shanghai, China
See details and how to joinNCT07754812 - No phaseTaking peoplectDNA-driven Adaptive Proton Craniospinal Irradiation in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis After Resistance to Third-Generation TKIs in the Consolidation Phase
- Where
- Hefei, Nanjing
- Életkor
- 18 év to 75 év
- People
- 84
- Run by
- Shuanghu Yuan
See details and how to joinNCT07751536 - No phaseNot yet taking people in KínaMicrobiota in Neoadjuvant Chemoimmunotherapy for NSCLC
- Where
- Guangzhou
- Életkor
- 18 év to 80 év
- People
- 100
- Run by
- Guangdong Provincial People's Hospital
See details and how to joinNCT07752589 - 3. fázisTaking peopleA Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
- Where
- Beijing, Changchun, Changsha, Chengdu, Chongqing, Haerbin, Hangzhou, Jiangxi, Jinan, Linyi, Neijiang, Shandong, Shanghai, Shenyang, Tianjin, Ürümqi, Wuhan, Xi'an, Xiangyang, Zhengzhou
- Életkor
- 18 év and over
- People
- 540 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06203210 · EU 2023-509628-16-00 - No phaseTaking peopleAnalgesic Effects of Retro-superior Costotransverse Ligament Space Block for Video-assisted Thoracoscopic Surgery
- Where
- Nanjing
- Életkor
- 18 év to 80 év
- People
- 130
- Run by
- Nanjing First Hospital, Nanjing Medical University
See details and how to joinNCT07745881